GMT Capital’s 4D Molecular Therapeutics FDMT Stock Holding History

GMT Capital’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-151,200	Closed	-$1.92M	–	66
2023 Q3	$1.92M	Buy	+151,200	New	+$2.53M	0.07%	71

Other funds holding FDMT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GMT Capital's FDMT Position: Q4 2023 in Review

GMT Capital sold out of 4D Molecular Therapeutics (FDMT) in Q4 2023, closing a stake of 151,200 shares — an estimated $1.92M sold.

GMT Capital first reported a position in FDMT in Q3 2023 and held it in 1 quarter. The position peaked at $1.92M in Q3 2023. 111 funds tracked by Wall St. Rank hold FDMT as of Q4 2023.

GMT Capital reported no remaining 4D Molecular Therapeutics position as of Q4 2023 after selling out during the quarter.
GMT Capital sold 151,200 4D Molecular Therapeutics shares in Q4 2023, an estimated $1.92M.
GMT Capital first reported a position in 4D Molecular Therapeutics in Q3 2023 and held it in 1 quarter.
GMT Capital's 4D Molecular Therapeutics position peaked at $1.92M in Q3 2023.
111 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q4 2023.

Based on GMT Capital's 13F filing for Q4 2023, filed 12 Feb 2024.